Skip Navigation


Rheumatology Advance Access originally published online on September 23, 2006
Rheumatology 2006 45(12):1572; doi:10.1093/rheumatology/kel335
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
45/12/1572    most recent
kel335v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Plastiras, S. C.
Right arrow Articles by Tzelepis, G. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Plastiras, S. C.
Right arrow Articles by Tzelepis, G. E.
Related Collections
Right arrow Systemic Sclerosis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

LETTERS TO THE EDITOR

Mycophenolate mofetil for interstitial lung disease in scleroderma

S. C. Plastiras, P. G. Vlachoyiannopoulos and G. E. Tzelepis

Department of Pathophysiology, University of Athens School of Medicine and Laiko University hospital, Athens, Greece

Correspondence to: G. E. Tzelepis, MD, University of Athens Medical School, Department of Pathophysiology, 75 M. Asias street, Athens, 11527 Greece. E-mail: gtzelep@med.uoa.gr

The first 10% of the full text of this article appears below.

SIR, In six patients with systemic sclerosis (SSc) and interstitial lung disease (ILD), Liossis et al. [1] reported pulmonary function improvements following first-line treatment with mycophenolate mofetil (MMF) for a period of 4–6 months. The improvements of lung diffusion capacity (DLCO), primarily, and to a lesser extent of forced vital capacity (FVC) along with radiological evidence of infiltrate . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
D. Daoussis, S.-N. C. Liossis, A. C. Tsamandas, C. Kalogeropoulou, A. Kazantzi, C. Sirinian, M. Karampetsou, G. Yiannopoulos, and A. P. Andonopoulos
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
Rheumatology, September 15, 2009; (2009) kep093v2.
[Abstract] [Full Text] [PDF]

Home page
 Med Decis MakingHome page
D. Khanna, D. E. Furst, P. J. Clements, D. P. Tashkin, and M. H. Eckman
Oral Cyclophosphamide for Active Scleroderma Lung Disease: A Decision Analysis
Med Decis Making, November 1, 2008; 28(6): 926 - 937.
[Abstract] [PDF]